Keros Therapeutics appoints Charles Newton to Board; Carl Gordon resigns effective March 9, 2026

Keros Therapeutics, Inc.

Carl Gordon, Ph.D., resigned from the Board and Compensation Committee, effective March 9, 2026; no disagreement with the Company.
Charles Newton appointed as Class III director, effective March 9, 2026, and will serve on Compensation and Audit Committees.
Newton is former CFO of Lyell Immunopharma and has held senior roles at Bank of America, Credit Suisse, and Morgan Stanley.
Newton currently serves on the boards of Novavax, Inc. and Coherus Oncology, Inc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.